Pharma IQ | 06/13/2010
The amorphous state is inherently instable. How do we keep amorphous forms from crystallising for as long as possible? Dr. Joseph Lubach from Genentech, joined Pharma IQ to discuss the challenges of physical and chemical stability, as well as techniques being implemented in the development of amorphous forms.
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More